TABLE 3.

Medication-Related Problems Identified by Site

	Site I1 n (%)	Site I2 n (%)	Site I3 n (%)	Site C1 n (%)	Site C2 n (%)	Total n (%)
Therapy duplications
Identified	3 (4.8)	4 (9.5)	2 (12.5)	16 (6.5)	5 (2.7)	30 (5.8)
Resolved	3 (100.0)	3 (75.0)	2 (100.0)	12 (75.0)	3 (60.0)	23 (76.6)
New duplications at follow-up	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.8)	0 (0.0)	2 (0.4)
Drug-disease interactions
Identified	1 (1.6)	1 (2.4)	0 (0.0)	11 (4.4)	2 (1.4)	15 (2.9)
Referred	0 (0.0)	0 (0.0)	0 (0.0)	5 (31.3)	1 (50.0)	6 (40.0)
Resolved	0 (0.0)	0 (0.0)	0 (0.0)	4 (80.0)	0 (0.0)	4 (66.7)
New interaction at follow-up	0 (0.0)	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.2)
Drug-drug interactions
Identified	5 (7.9)	2 (4.8)	0 (0.0)	29 (11.7)a	6 (4.1)	42 (8.1)
Referred	3 (60.0)	0 (0.0)	0 (0.0)	10 (34.5)	2 (33.3)	15 (35.7)
Resolved	1 (33.3)	0 (0.0)	0 (0.0)	4 (40.0)	2 (100.0)	7 (46.6)
Safety concerns
Identified	7 (11.1)	5 (11.9)	0 (0.0)	35 (14.1)	8 (5.4)	55 (10.6)
Referred	4 (57.1)	3 (60.0)	0 (0.0)	29 (82.9)	7 (87.5)	43 (78.2)
Resolved	4 (100.0)	0 (0.0)	0 (0.0)	4 (13.8)	1 (14.3)	9 (20.9)
Dose-related concerns identified
Too high	3 (42.9)	2 (40.0)	0 (0.0)	13 (44.8)	4 (50.0)b	22 (40.0)
Too low	2 (28.6)	3 (60.0)	0 (0.0)	22 (62.9)	4 (50.0)	31 (56.4)
Other	2 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.6)
Adverse drug reactions identified	14 (22.2)	7 (16.7)	3 (18.8)	46 (18.5)	18 (12.2)	88 (17.0)
Medication interventions						237
Interventions per patient						0.46

Notes: Sites I1, I2, and I3 = independent community pharmacies; sites C1 and C2 = community health center pharmacies. Percentages may not equal 100% due to rounding.

^aC1 had a higher proportion of drug-drug interactions identified than C2 (P = 0.016).

^bC1 had a higher number of dose-related concerns than C2 (P = 0.011).